After the Green Rush: Cannabis Stocks in 2020

In January of 2018, Aurora Cannabis Inc. (TSX:ACB)(NASDAQ:ACB) promoted long-time head of investor relations Cam Battley to the position of Chief Corporate Officer. Battley had earned it. The Aurora stock price was cresting at $14 as the well-traveled and often re-told story about Aurora’s ambitious plan to build a series of industrial-sized, fully automated greenhouses […]

The post After the Green Rush: Cannabis Stocks in 2020 appeared first on Latest Cannabis News Today – Headlines, Videos & Stocks.

The Cannabis Stock Bounce – some good news

As we write this, the top six most active symbols by volume on the TSX are cannabis stocks. Cannabis companies were also four of the top five traders on the TSX-Venture by volume and seven of the top ten volume traders on the CSE. Relative trading volume is the most objective way to measure what […]

The post The Cannabis Stock Bounce – some good news appeared first on Latest Cannabis News Today – Headlines, Videos & Stocks.

Aurora Cannabis shares fall after CCO Cam Battley steps down

EDMONTON — Shares in Aurora Cannabis Inc. fell to their lowest level in more than two years Monday after the announcement on the weekend that Cam Battley had suddenly stepped down as chief corporate officer. The stock fell by about 9.8 per cent to as low as $2.66 in trading on the Toronto Stock Exchange, down from its […]

The post Aurora Cannabis shares fall after CCO Cam Battley steps down appeared first on Cannabis News | Lifestyle Tips | Expert Opinions | Stocks.

Ireland Approves Two Canadian Firms To Supply Medical Cannabis

Two Canadian companies have been approved as the first suppliers to the recently launched medical cannabis program in Ireland.

The Irish Government signed off on the launch of its five-year pilot in June, and now Aurora and MGC Pharmaceuticals have been selected to provide its first cannabis medicine.

Under the scheme consultants can prescribe to patients with spasticity, associated with multiple sclerosis, chemotherapy-related intractable nausea and treatment-resistant epilepsy. The two products are Aurora High CBD Oil Drops and CannEpil, both are CBD based drugs with the latter being used to treat epilepsy.

Looking for the BEST CBD products for your shop?
CLICK HERE or use the sign up form below to subscribe to the
CBD Business Weekly Newsletter.

Weeks To Wait

However, much like its U.K. neighbor there will be a time-lag of weeks between prescription and receipt of the drug. The Irish Journal reports that under the scheme the two companies have to apply for a licence to bring the product into Ireland for distribution. 

CannEpil is a product that ‘has been years in the making’, and was released into the market in 2017, says Roby Zomer, Executive Director and CEO at MGC. Dr Shane Morris, Chief Product Officer at Aurora said: “We are very proud to be one of the first approved suppliers of medical cannabis…and will continue to work closely with all parties and state agencies to facilitate further availability.”

The Medical Cannabis Access Programme was signed into law in June this year, by the Minister for Health in Ireland, Simon Harris. 

80,000 New Jobs

Mr Harris said at the time that the program would allow ‘compassionate access to cannabis for medical reasons’ in cases where conventional treatment has failed. The Irish Government says it wants to encourage the development of a home-grown cannabis cultivation and hemp industry saying it the potential to create over 80,000 jobs.

Meanwhile, a third Canadian company Province Brands of Canada, has appointed Irish drinks distributor Barry & Fitzwilliam, as its distribution partner to bring its  non-alcoholic CBD beer to the Irish consumer.

Barry & Fitzwilliam is Ireland’s largest independent drinks distributor, and the new venture is expected to begin offering CBD-infused, barley-based, non-alcoholic beverages across Ireland in February 2020.

For more stories like this one, subscribe to the CBD Business Weekly Newsletter.

The post Ireland Approves Two Canadian Firms To Supply Medical Cannabis appeared first on CBD Testers.

Aurora Receives First Approval for Medicinal Cannabis Product in Ireland

TSX | NYSE: ACB    EDMONTON, Dec. 2, 2019 /CNW/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE │ TSX: ACB), the Canadian company defining the future of cannabis worldwide, today announced that one of the Company’s oil products has now been approved for use under Ireland’s new Medical Cannabis Access Programme (MCAP). Aurora’s High CBD […]

The post Aurora Receives First Approval for Medicinal Cannabis Product in Ireland appeared first on Cannabis News | Lifestyle Tips | Expert Opinions | Stocks.

Aurora Cannabis Opens Experiential Flagship Store in North America’s Largest Mall

11,000 Square Foot Retail Destination and Global Centre for Cannabis Education, Discovery and Community Engagement TSX | NYSE: ACB  EDMONTON, Nov. 27, 2019 /CNW/ – Aurora Cannabis Inc. (“Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, today announced the grand opening of its flagship retail store at 10:00 a.m. MT […]

The post Aurora Cannabis Opens Experiential Flagship Store in North America’s Largest Mall appeared first on Cannabis News | Lifestyle Tips | Expert Opinions | Stocks.

Aurora shares sink on weak results

Aurora Cannabis Inc. shares sank to a two-year low Friday after its revenues missed expectations and the pot producer announced it was halting construction of two production facilities to save over $190 million in planned expenses. The Edmonton-based company’s shares fell to a low of $3.59 and were down 51 cents or 11.6 per cent at $3.87 in afternoon trading on the […]

The post Aurora shares sink on weak results appeared first on Cannabis News | Lifestyle Tips | Expert Opinions | Stocks.

Medical Cannabis Patients in Germany Set To Top One Million

A new report into the German cannabis market estimates the total number of patients has risen 60,000 in less than two years since first approved for medical use.

The ‘Germany Cannabis Report’ from Prohibition Partners also states that within a few years that number will have risen to one million patients. And, it estimates the total German cannabis market will be worth €16.2 billion by 2028, with the medicinal cannabis market estimated to be worth €7.7 billion by the same time.

This comes as Canadian firm Aphria, one of the few from that country to be currently showing a profit, says that by next year Germany will be contributing almost half its revenues. 


German Boost For Aphria

In a first quarter results announcement Aphria said with 2020 revenue projections estimated at $700 million, its ‘German distribution business will represent slightly more than half of the total net revenue’. 

Daragh Anglim, Managing Director Prohibition Partners, says in the introduction to the report, released in mid-October, that the rapid growth of the German market ‘is unprecedented in Europe’. 

Adding: “Major change has followed across the continent but Germany remains one of the most open, promising and exciting markets in the region.” 

The report highlights the supply problems facing the German market which is currently reliant on imports from Canada, Holland, Portugal and Australia. In an effort to combat this production licences were granted earlier this year, and of the 13 lots, Aphria and Aurora secured five, and Demecan received the remaining three lots. 

23 Euros Per Gram

Each lot allows the holder to grow 200 kilograms per year for a four-year period. And the report adds: “The reality is that the German tendered facilities are not going to meet the domestic medical cannabis quantity demand.” 

It says patients requesting medicinal cannabis are being supported by a robust public health insurance regime, which covers 90% of the population. The monthly allowance 100 gramme is generous and the ‘insurance companies cover all cannabis treatments and do not specify which conditions are covered’. 

Medicinal cannabis in Germany is very expensive, however, with an average price to patients of between €20 and €25 per gram for flower. In the Netherlands, medical cannabis is sold to patients for approximately €7 per gram, says the report.

For more stories like this one, subscribe to the CBD Business Weekly Newsletter.

The post Medical Cannabis Patients in Germany Set To Top One Million appeared first on CBD Testers.

Tech Investors Enter German Medical Cannabis Market

German tech investors have taken their first step into the cannabis space backing leading domestic business, Demecan.

The Berlin-based company was the only German firm to secure one of three cultivation contracts to support the country’s blossoming medical cannabis market. And Demecan has now secured the support of btov Partners which has previously invested in tech startups such as Facebook, DeepL, Foodspring, Blacklane, and Data Artisans, reports the TechCrunch website.

In a 7 million Euro funding round initiated by Demecan Btov was one of two major contributors, with the second being a network of high-net worth individuals.


First-Mover Advantage

The cash will be used to expand Demecan’s production facilities for medical cannabis and support the development of its wholesale network across Germany. Jennifer Phan, of btov, which manages assets of 420 million Euros, said Demecan benefits from ‘first-mover advantage in a highly regulated market’ and is ‘the only German manufacturing and trading company in the European market’.

Germany legalized cannabis medication in 2017 and there were an estimated 30,000 patients by the end of  2018, with imports of cannabis totaling 22,000 kilograms. Earlier this year Canadian companies Aphria and Aurora and Demecan successfully bid to win licences to supply the German market which is currently reliant on imports from Holland and Canada.

Further Supply Opportunities

The licensing regime, approved by Germany’s Federal Institute for Drugs and Medical Devices, means Demecan will be able to produce at least 2,400 kilograms of dried cannabis flowers over the next four years. The company is also an active importer and wholesaler of medical cannabis. 

Meanwhile Canadian company Quality Green, says it has designs on the German market with applications for export licenses pending, reports Investing News website. If successful the company says it will begin exporting next year, as it believes the cultivation licences issued to Demecan and the two Canadian firms will not be sufficient to meet with demand.

Germany is seen as the biggest European market opportunity with an advanced medical cannabis program and a population of 90 million. It is attracting major overseas investment, and the investment into Demecan is one of the first major homegrown investments into the cannabis industry.

For more stories like this one, subscribe to the CBD Business Weekly Newsletter.

The post Tech Investors Enter German Medical Cannabis Market appeared first on CBD Testers.

Aurora Cannabis Announces Financial Results for the Fourth Quarter and 2019 Fiscal Year

Aurora Cannabis Generates Net Revenue of $98.9 Million, Up 52% From Prior QuarterCannabis Net Revenue Increases 61% to $94.6 Million From Prior QuarterReports Gross Margin on Cannabis Net Revenue of 58% TSX: ACB | NYSE: ACB EDMONTON, Sept. 11, 2019 /CNW/ – Aurora Cannabis Inc. (the “Company” or “Aurora“) (NYSE | TSX: ACB), the Canadian company […]

The post Aurora Cannabis Announces Financial Results for the Fourth Quarter and 2019 Fiscal Year appeared first on Cannabis News | Lifestyle Tips | Expert Opinions | Stocks.